Business Wire

Western Union Foundation Announces New Partnerships to Advance Vaccine Education & Workforce Training in Q1/2021

8.4.2021 15:00:00 EEST | Business Wire | Press release

Share

The Western Union Foundation today announced its first-quarter 2021 programs, investing more than USD 1.25 million to mobilize youth to access jobs in the healthcare industry, assisting with COVID-19 vaccine education and distribution, and to enable economic recovery through workforce training. This investment furthers the Western Union Foundation’s Opportunity Beyond Borders three-year USD 15 million commitment to provide migrant and young adults with resources to gain sustainable employment and provide relief and preparedness for crises.

“The Western Union Foundation recognizes that this moment—as the global pandemic recovery effort begins in earnest—is a crucial one for the communities we serve,” said Foundation Executive Director Elizabeth Roscoe. “We are determined to do everything we can to keep people who are already on the margins from falling farther behind because they lack access to vaccines or opportunities to participate in the formal labor markets as economies progress toward recovery.”

In 2020, the first full year of Opportunity Beyond Borders, the Western Union Foundation invested more than USD 6 million to help 200,000 people in 33 countries, as detailed in its 2020 Global Impact Report.

COVID-19 vaccine education, preparedness, and distribution programs

Research has shown a large portion of the population in many low-income countries is hesitant to get the vaccine, often due to lack of education about the vaccine and logistical challenges to reach vaccine centers. The Aspen Institute and International Medical Corps will receive funds from the Western Union Foundation to address these challenges.

In Kenya and India, the Aspen Institute will partner with leading community-based organizations to support vaccine education and distribution efforts by skilling youth and women in the community in vaccine awareness, preparedness and access.

In the Philippines, the International Medical Corps program will address vaccine hesitancy by driving awareness and coordinating transportation for vulnerable populations to vaccine centers.

In Pakistan, host to the third-largest number of refugees in the world, International Medical Corps will train volunteers in refugee villages to raise vaccine awareness and promote health and hygiene best practices.

Western Union and the Foundation are further enabling vaccine adoption by donating funds on behalf of each vaccinated Western Union employee and allowing employees to donate directly to the cause. This program will provide up to $350K to help inoculate thousands more in rural communities.

Workforce training for entrepreneurship and career pathways

In addition to the COVID-19 community resilience programs, the Foundation’s first-quarter investment aims to enable economic recovery for migrant and refugee communities affected by last year’s lockdowns. The following are a few of the programs:

In Mexico, the Whitaker Peace & Development Initiative will scale entrepreneurship programs by training young business leaders and incubating micro-businesses that provide essential services and products to their local communities.

In Jordan and Lebanon, the Kiron Open Higher Education program will work with the most vulnerable populations residing in refugee encampments and will offer skill-building opportunities to prepare individuals for and give access to career pathways.

In Jordan and Palestine, Education for Employment will launch a research study about relevant jobs post-COVID-19 and provide customized training to business owners, with the majority female, helping them adapt and grow their businesses in response to the effects of COVID-19.

To learn more about the impact the Western Union Foundation has made to people and partners over the past year, check out the stories of impact on their newly launched website.

About the Western Union Foundation

The Western Union Foundation believes that education is the surest pathway to economic opportunity. After 20 years of impact, we continue to deliver on our mission with Opportunity Beyond Borders, focused on empowering forcibly displaced and marginalized youth with the training and education needed to succeed in today’s technology-driven global economy. The Foundation also provides funding for humanitarian efforts for communities in crisis and disaster, one key reason for forced migration. To date, we have funded more than $131 million for projects and scholarships. The Western Union Foundation is a separate, tax-exempt 501(c)(3) charitable corporation and receives support from The Western Union Company, its employees, agents, and business partners. Contributions to the Foundation are tax-deductible for U.S. income tax purposes. To learn more, visit www.westernunionfoundation.org or follow us on Twitter @TheWUFoundation.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For further information please contact:
Western Union Global Communications; Pia De Lima; Pia.DeLima@wu.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release

Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o

Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release

Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a

DAYBU ® (trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 13:49:00 EEST | Press release

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating condition," said Catherine Owen Adams, Acadia’s Chief Executive Officer. “Our commitment is to make a meaningful difference in the lives of patients, caregivers, and the wider Rett com

HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 12:18:00 EEST | Press release

HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi

Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 11:28:00 EEST | Press release

Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye